COPD is the third leading cause of death worldwide ... with improvements in lung function and health-related quality of life scores. Regeneron’s chief scientific officer, George Yancopolous ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Some of the early signs of chronic obstructive pulmonary disease (COPD) are an ongoing cough, increased mucus, and fatigue. Recognizing these symptoms is important to know whether you need to see ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

Read about the latest analyst upgrades and downgrades on major stocks like AMD, Skyworks, Palantir, Nike, and more in this ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...